Bromocriptine and insulin sensitivity in lean and obese subjects

Area of Science:

• Metabolic Medicine
• Endocrinology
• Pharmacology

Background:

• Bromocriptine is a glucose-lowering medication.
• Its effectiveness in obese individuals with insulin resistance is established.
• The precise mechanism and optimal administration timing remain unclear.

Purpose of the Study:

• To investigate the impact of bromocriptine administration timing (morning vs. evening) on insulin sensitivity.
• To compare these effects between lean and obese subjects.
• To elucidate the mechanistic effects of bromocriptine.

Main Methods:

• An open-label, randomized, prospective, cross-over study.
• 8 lean and 8 overweight subjects participated.
• Oral glucose tolerance tests were conducted after 2 weeks of morning and 2 weeks of evening bromocriptine administration.

Main Results:

• In lean subjects, evening bromocriptine significantly increased post-prandial insulin sensitivity.
• In obese subjects, both morning and evening bromocriptine administration significantly improved insulin sensitivity.
• Specific glucose and insulin AUC changes were noted in both groups, with varying statistical significance.

Conclusions:

• Bromocriptine enhances insulin sensitivity in both lean and obese individuals.
• For lean individuals, evening administration is key for this effect.
• Obese individuals experience improved insulin sensitivity irrespective of bromocriptine administration timing.